Traders work on the floor of the New York Stock Exchange (NYSE) on the first day back since the Christmas holiday on December 26, 2023 in New York City.In each of the past 16 Decembers I have selected and invested personally in 10 of the stocks we follow with the intention of holding for just one year. These are companies that I find especially attractive in light of their valuations or their potential to benefit from economic developments. I hold an equal dollar amount in each of the positions for the foll ...

A tree with $100 U.S. banknotes as leaves. DNY59 Familiar readers are probably well aware that I am a dividend growth investor. For the last 15 years, I have known about the strategy. It wasn't until I finished my first two years of undergrad and began to generate excess income that I started investing, however. But in the last six years, I have been laser-focused on stuffing my portfolio with many of the best businesses in the world. This is because I have both theoretically and practically found that owni ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-2189 ABBOTT LABORATORIES An Illinois Corporation I.R.S. Employer Identification No. 36-0698440 100 Abbott Park Road Abbott Park, ...

Abbott Laboratories (NYSE:ABT) Q3 2023 Earnings Call Transcript October 18, 2023 9:00 AM ET Company Participants Mike Comilla - Vice President, Investor Relations Robert Ford - Chairman and Chief Executive Officer Philip Boudreau - Senior Vice President, Finance and Chief Financial Officer Conference Call Participants Joshua Jennings - TD Cowen Larry Biegelsen - Wells Fargo Robbie Marcus - JPMorgan Danielle Antalffy - UBS Joanne Wuensch - Citibank Vijay Kumar - Evercore ISI Matt Miksic - Barclays Jayson Bed ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-2189 ABBOTT LABORATORIES An Illinois Corporation I.R.S. Employer Identification No. 36-0698440 100 Abbott Park Road Abbott Park, Illin ...

Abbott Laboratories (NYSE:ABT) Q2 2023 Earnings Conference Call July 20, 2023 9:30 AM ET Company Participants Mike Comilla - Vice President, Investor Relations Robert Ford - Chairman and Chief Executive Officer Bob Funck - Executive Vice President, Finance and Chief Financial Officer Conference Call Participants Joshua Jennings - TD Cowen Larry Biegelsen - Wells Fargo Danielle Antalffy - UBS Vijay Kumar - Evercore ISI Joanne Wuensch - Citi Marie Thibault - BTIG Matt Miksic - Barclays Jayson Bedford - Raymon ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-2189 ABBOTT LABORATORIES An Illinois Corporation I.R.S. Employer Identification No. 36-0698440 100 Abbott Park Road Abbott Park, Illi ...

Abbott Laboratories (NYSE:ABT) Q1 2023 Earnings Conference Call April 19, 2023 9:00 AM ET Company Participants Scott Leinenweber - Vice President, Investor Relations Robert Ford - Chairman and Chief Executive Officer Bob Funck - Executive Vice President, Finance and Chief Financial Officer Conference Call Participants Larry Biegelsen - Wells Fargo Joshua Jennings - Cowen Robbie Marcus - JPMorgan Rick Wise - Stifel Vijay Kumar - Evercore ISI Joanne Wuensch - Citi Danielle Antalffy - UBS Matt Miksic - Barclay ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 ______________________________________________ FORM 10-K (MARK ONE) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ________________________________________________________ For the fiscal year ended December 31, 2022 Commission file number 1-2189 Abbott Laboratories An Illinois Corporation 36-0698440 100 ...

Financial Data and Key Metrics Changes - For the full year 2022, the company achieved ongoing earnings per share of $5.34, exceeding the original EPS guidance set at the beginning of the year [5] - The company forecasts ongoing earnings per share for 2023 to be between $4.30 and $4.50, with organic sales growth, excluding COVID testing sales, expected in the high single-digits [10][20] - Total sales decreased 6.1% on an organic basis in the fourth quarter, but excluding COVID testing and U.S. infant formula sales, total sales increased 7.1% in the fourth quarter and 7.4% for the full year 2022 [18] Business Line Data and Key Metrics Changes - Nutrition sales declined around 6% in both the fourth quarter and full year due to manufacturing disruptions at a U.S. infant formula facility, but production is recovering [11] - Diagnostics sales growth in the fourth quarter was negatively impacted by a decline in COVID-19 test sales, which were $1.1 billion, while excluding COVID testing, worldwide diagnostics grew over 11% [12][13] - Established Pharmaceuticals (EPD) sales increased 8% in the fourth quarter and over 10% for the full year, driven by strong performance in emerging markets [14] - Medical devices sales grew 7.5% in the fourth quarter and 8% for the full year, with significant growth in electrophysiology and diabetes care [15] Market Data and Key Metrics Changes - The company noted that the U.S. dollar weakened somewhat and inflation eased, contributing to a more favorable operating environment [6][7] - The company expects COVID-19 testing sales to decline significantly as the virus transitions to a more endemic seasonal type [10] Company Strategy and Development Direction - The company aims to strengthen its strategic position in diagnostics and expand investments in priority growth areas, including R&D and new product launches [9][10] - The company is optimistic about growth opportunities across all business lines and plans to leverage its strong balance sheet for future growth [16][20] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism about the easing of macroeconomic challenges, including inflation and supply chain issues, while acknowledging that these factors remain headwinds [6][10] - The company anticipates a steady improvement in procedure trends and expects to recover market share in the Nutrition segment [30][52] Other Important Information - The adjusted gross margin ratio was 55.6% of sales in the fourth quarter, reflecting the impact of manufacturing disruptions and inflation [19] - The company plans to invest approximately $2.5 billion in R&D and around $11 billion in SG&A for the year [20] Q&A Session Summary Question: How should the guidance range be interpreted given the various business lines and macro factors? - Management indicated that the guidance reflects improvements in the macro environment and stabilization in business segments, excluding COVID testing and recall impacts [24][26] Question: What is the expected quarterly cadence for 2023? - Management expects earnings to build throughout the year, with a forecast of approximately $1 in earnings for the first quarter, improving as new product launches and recovery in procedures take effect [30] Question: What is the outlook for the FreeStyle Libre product? - Management expects continued growth in the U.S. and internationally, with potential for over 20% growth in 2023, driven by market expansion and resolution of supply chain issues [35][36] Question: What are the company's plans for share repurchases and cash use? - The company prioritizes a strong and growing dividend, with plans for share repurchases focused on offsetting dilution and ensuring resources for new product launches [54] Question: What are the assumptions for organic growth in 2023? - Management noted that while there are macro headwinds, the reopening of China and improvements in procedure trends are expected to positively impact growth [57]